Tag: Hiv pharmacology

Approved by the FDA in 1996, Crixivan (indinavir) was a landmark protease inhibitor in the fight against HIV, but its mechanism is key to understanding how does Crixivan work to halt viral replication. It was one of the first highly effective drugs to transform HIV from a rapidly fatal illness into a manageable chronic condition, ushering in the era of highly active antiretroviral therapy (HAART).

Islatravir is a potent, investigational antiretroviral drug developed by Merck for the treatment of HIV. Its unique mechanism of action places it in a new class of HIV medications known as the nucleoside reverse transcriptase translocation inhibitors (NRTTIs).